Karmanos Offers FDA-Approved Daraxonrasib for Cancer
Detroit, Michigan, August 31, 2026 The Barbara Ann Karmanos Cancer Institute announced that it is now offering FDA-approved daraxonrasib...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Detroit, Michigan, August 31, 2026 The Barbara Ann Karmanos Cancer Institute announced that it is now offering FDA-approved daraxonrasib...
REDWOOD CITY, Calif., August 26, 2026 Revolution Medicines, Inc. has received U.S. Food and Drug Administration (FDA) approval for...
